Atrioventricular Nodal Reentry Tachycardia Treatment & Management
- Author: Brian Olshansky, MD; Chief Editor: Jeffrey N Rottman, MD more...
Rest, reassurance, sedation, and/or vagal maneuvers may terminate an attack of atrioventricular nodal reentry tachycardia (AVNRT). The successful management of an acute attack, however, depends on the symptoms, the presence of underlying heart disease, and the natural history of previous episodes.
In the presence of a wide-complex tachycardia, the institution of therapy should always follow a careful review of the patient's prior cardiac history, including left ventricular function and previous ECGs, which are helpful tools for defining the origin of the arrhythmia (ie, supraventricular vs ventricular).
The use of calcium channel blockers is contraindicated in patients with tachycardias of ventricular origin and may cause hemodynamic compromise and death.
To terminate AVNRT, try vagal maneuvers (eg, carotid sinus massage, exposure of the face to ice water, Valsalva maneuver) before initiating drug treatment. These maneuvers can also be tried after each pharmacologic approach. Vagal maneuvers are unlikely to work and should not be tried if hypotension is present. Sometimes, putting the patient in the Trendelenburg position facilitates termination with a vagal maneuver.
Direct-current synchronized cardioversion
Direct-current (DC) synchronized cardioversion is used to terminate an attack if the patient has hemodynamic compromise or if drug conversion fails and the patient continues to be symptomatic. However, DC cardioversion is rarely necessary for AVNRT.
Competitive atrial or ventricular pacing may be used if DC cardioversion is contraindicated (eg, if high doses of digitalis have been administered).
No specific recommendations or restrictions are necessary, but some patients' episodes are exacerbated by caffeine, theophylline, or theobromine in selected foods (coffee, tea, or chocolate, respectively). Alcohol may also be a trigger.
Advise the patient to rest during tachycardia, preferably in a supine position.
Consultations include the following:
Transfer to a facility capable of performing electrophysiologic studies and radiofrequency ablation may be needed.
Drugs that can be used to terminate an attack include adenosine, calcium channel blockers (eg, diltiazem, verapamil), beta-blockers, and digitalis.
Adenosine is the first-line drug used for termination of AVNRT. In rare cases, the administration of adenosine may lead to atrial fibrillation or even asystole for a short period.
Adenosine administration should be given through a central, large bore intravenous (IV) needle, as it has a very short half-life. It should be followed by a saline flush and elevation of the extremity in which it is being injected. The initial dose is 6 mg followed by 12 mg and occasionally 18 mg. It should not be used in heart transplantation patients, it may be ineffective if given to a patient taking theophylline, and it may be potentiated by dipyridamole.
Preventive therapy is needed for frequent, prolonged, or highly symptomatic episodes that do not terminate spontaneously or for those that cannot be easily terminated by the patient. Drugs that are used for prevention of recurrence include long-acting beta-blockers, calcium channel blockers, and digitalis.
Radiofrequency Catheter Ablation
Radiofrequency catheter ablation of the reentrant circuit should be considered in patients who have frequent or highly symptomatic episodes, who do not want drug therapy, who cannot tolerate the drugs, or in whom drug therapy fails.
Radiofrequency catheter ablation is associated with cure rates of greater than 95%, with very low risk of AV block (< 1%) for patients with AVNRT. This is an invasive procedure in which catheter electrodes are placed percutaneously via central veins into the heart. Tachycardia can be initiated by pacing and by programmed electrical stimulation delivered from the atria or the ventricles.
An ablation catheter electrode can be placed in the location of the slow AV nodal pathway, with radiofrequency energy delivered via the catheter to interrupt conduction via this pathway and thus eliminate the circuit.
Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, Pa: WB Saunders; 2004.
Janse MJ, Anderson RH, McGuire MA, Ho SY. "AV nodal" reentry: Part I: "AV nodal" reentry revisited. J Cardiovasc Electrophysiol. 1993 Oct. 4(5):561-72. [Medline].
Hanninen M, Yeung-Lai-Wah N, Massel D, Gula LJ, Skanes AC, Yee R, et al. Cryoablation versus RF ablation for AVNRT: A meta-analysis and systematic review. J Cardiovasc Electrophysiol. 2013 Dec. 24(12):1354-60. [Medline].
Gursoy S, Steurer G, Brugada J, et al. Brief report: the hemodynamic mechanism of pounding in the neck in atrioventricular nodal reentrant tachycardia. N Engl J Med. 1992 Sep 10. 327(11):772-4. [Medline].
Fogoros RN. Electrophysiologic Testing (Practical Cardiac Diagnosis). 3rd ed. London, UK: Blackwell Science; 1999.
Jackman WM, Beckman KJ, McClelland JH, et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med. 1992 Jul 30. 327(5):313-8. [Medline].